Table 2.

Effect of allocation to tocilizumab on main study outcomes

		Treatment allocation		RR (95% CI)	p value
		Tocilizumab group (n=2022)	Usual care group (n=2094)
Primary outcome
28-day mortality		621 (31%)	729 (35%)	0·85 (0·76–0·94)	0·0028
Secondary outcomes
Median time to being discharged, days		19	>28	··	··
Discharged from hospital within 28 days		1150 (57%)	1044 (50%)	1·22 (1·12–1·33)	<0·0001
Receipt of invasive mechanical ventilation or death*		619/1754 (35%)	754/1800 (42%)	0·84 (0·77–0·92)	<0·0001
	Invasive mechanical ventilation	265/1754 (15%)	343/1800 (19%)	0·79 (0·69–0·92)	0·0019
	Death	490/1754 (28%)	580/1800 (32%)	0·87 (0·78–0·96)	0·0055
Subsidiary clinical outcomes
Receipt of ventilation†		290/935 (31%)	323/933 (35%)	0·90 (0·79–1·02)	0·10
	Non-invasive ventilation	281/935 (30%)	309/933 (33%)	0·91 (0·79–1·04)	0·15
	Invasive mechanical ventilation	67/935 (7%)	86/933 (9%)	0·78 (0·57–1·06)	0·11
Successful cessation of invasive mechanical ventilation‡		95/268 (35%)	98/294 (33%)	1·08 (0·81–1·43)	0·60
Use of haemodialysis or haemofiltration§		120/1994 (6%)	172/2065 (8%)	0·72 (0·58–0·90)	0·0046

Data are n (%), n/N (%), or median (IQR) unless stated otherwise. RR=rate ratio for the outcomes of 28-day mortality, hospital discharge, and successful cessation of invasive mechanical ventilation, and risk ratio for other outcomes.

^*Analyses include only those on no ventilator support or non-invasive ventilation at second randomisation.

^†Analyses include only those on no ventilator support at second randomisation.

^‡Analyses restricted to those on invasive mechanical ventilation at second randomisation.

^§Analyses exclude those on haemodialysis or haemofiltration at second randomisation.